37 completed, 7 withdrawn, 5 recruiting, 5 unknown. 16 Phase 1, 16 Phase 4, 12 Phase 2, 11 Phase 3, 5 Not applicable.
Follow Oxymetazoline: new trials by email Literature Review of Oxymetazoline trials Research Report on Oxymetazoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Upneeq vs. Lumify Ptosis Oxymetazoline 0.1% (Upneeq), Brimonidine 0.025% (Lumify) - Acquired Ptosis | Phase 4 | Not yet recruiting | Duke University | 50 | 2026-12-01 | 2026-05-22 |
| Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars Oxymetazoline 0.05% nasal solution, Sodium Hypochlorite Solution - Pulp Disease, Dental, Pulp Therapy in Primary Molars | Not applicable | Not yet recruiting | Cairo University | 50 | 2026-08-01 | 2026-06-30 |
| A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults Oxymetazoline HCl 0.05% nasal gel, Placebo nasal gel - Nasal Congestion, Nasal Obstruction | Phase 2 | Completed | Bayer | 120 | 2026-04-20 | 2026-06-08 |
| Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants Oxymetazoline + Triamcinolone - Nasal Obstruction, Chronic Rhinitis | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2025-11-10 | 2026-03-23 |
| Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia. Decongestant nasal spray (oxymetazoline hydrochloride (0.05%)), PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02% - Perioperative Respiratory Adverse Events, Anesthesia Outcomes | Phase 4 | Recruiting | Telethon Kids Institute | 200 | 2025-06-25 | 2025-11-19 |
| Oxymetazoline Bridge Therapy With Intranasal Corticosteroids in Pediatric Allergic Rhinitis Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg, Oxymetazoline 0.05% nasal solution - Persistent Allergic Rhinitis | Phase 4 | Completed | Dr. Behcet Uz Children's Hospital | 76 | 2025-01-02 | 2026-05-18 |
| LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers, Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers - Acquired Blepharophimosis | Phase 3 | Recruiting | Santen SAS | 234 | 2024-12-30 | 2026-05-04 |
| Nasal Obstruction With Oxymetazoline and Corticosteroids Oxymetazoline Nasal Spray, Budesonide nasal spray - Nasal Obstruction | Phase 2 | Recruiting | Washington University School of Medicine | 80 | 2024-10-15 | 2025-09-11 |
| Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery Local Anesthesia (lidocaine hydrochloride), Iontophoresis of Tetracaine and oxymetazoline - Local Anesthesia Injection Pain | Early Phase 1 | Completed | Louisiana State University Health Sciences Center in New Orleans | 20 | 2024-08-01 | 2025-11-19 |
| Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops - Blepharoptosis, Synkinesis | Phase 3 | Completed | Milton S. Hershey Medical Center | 36 | 2024-01-11 | 2026-03-09 |
| Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea Oxymetazoline Hydrochloride, Placebo - Sleep Apnea, Chronic Nasal Congestion | Phase 4 | Recruiting | University of South Florida | 52 | 2023-04-01 | 2025-01-24 |
| The Role of Nasal Breathing for Perfomance in Elite Athletes. Oxymetazoline, 0.05% Nasal Spray - Breathing, Mouth | Not applicable | Completed | Sahlgrenska University Hospital | 12 | 2022-01-13 | 2024-07-01 |
| Clinical Trial of Anusol Ointment for Symptom Relief in Patients With Haemorrhoids Anusol, Relief [Name], Placebo - Hemorrhoids | Phase 3 | Completed | Church & Dwight Company, Inc. | 66 | 2021-11-25 | 2022-08-15 |
| Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound - Presbyopia | Phase 1 | Unknown | Optall Vision | 11 | 2021-08-14 | 2021-08-17 |
| Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac, Pilocarpine Hydrochloride, Brimonidine Tartrate - Presbyopia | Phase 1 | Unknown | Optall Vision | 11 | 2021-08-10 | 2021-08-19 |
| The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo - Ptosis, Eyelid, Conjunctiva Inflamed | Phase 4 | Completed | University of Miami | 114 | 2021-06-08 | 2023-04-24 |
| Use of Phenylephrine for Assessment of Mitral Regurgitation Severity Mydfrin - Mitral Regurgitation | Phase 1 / Phase 2 | Recruiting | Montefiore Medical Center | 35 | 2020-12-01 | 2025-07-20 |
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General Kovanaze Nasal Spray, Articaine Injection - Caries,Dental, Apical Periodontitis | Phase 2 | Withdrawn | Virginia Commonwealth University | 2020-09-01 | 2024-10-15 | |
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics Kovanaze Nasal Spray, Articaine Injection - Caries,Dental, Apical Periodontitis | Phase 2 | Withdrawn | Virginia Commonwealth University | 2020-08-01 | 2020-06-25 | |
| Compound to Control Presbyopia Symptoms PBO to control presbyopia symptoms - Presbyopia | Phase 1 | Completed | Optall Vision | 11 | 2020-06-01 | 2021-08-19 |
Showing 20 of 59. Sign in to see all of them.
Nasal Obstruction (8) · Rhinitis, Allergic (7) · Rhinitis (4) · Rosacea (4) · Blepharoptosis (3) · Dental Caries (3) · Periapical Periodontitis (3) · Presbyopia (3) · Respiratory Tract Infections (3) · Dental Pulp Diseases (2) · Erythema (2) · Rhinitis, Allergic, Seasonal (2) · Arrhythmias, Cardiac (1) · Cataract (1) · Common Cold (1)
Bayer (5) · Optall Vision (3) · Virginia Commonwealth University (3) · Brian J Lipworth (2) · Egalet Ltd (2) · GlaxoSmithKline (2) · Johnson & Johnson Consumer and Personal Products Worldwide (2) · Louisiana State University Health Sciences Center in New Orleans (2) · Richard Cartabuke (2) · University of South Florida (2) · Washington University School of Medicine (2) · Aclaris Therapeutics, Inc. (1) · Actavis Inc. (1) · Association Asthma, Bulgaria (1) · Cairo University (1)
United States (26) · United Kingdom (4) · Mexico (3) · Australia (2) · Brazil (2) · Canada (2) · Germany (2) · Armenia (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Egypt (1) · France (1) · Hungary (1) · Italy (1)
Parthasarathy Madurantakam, DDS, PhD (3) · Brian Lipworth, MD, FRCP (2) · Cesar Alejandro S Galeana, MD (2) · Richard Cartabuke, MD (2) · Annahita Ghassemi, PhD (1) · Anup Acharya, MS (1) · Cesar Alejandro S Galeana (1) · Christopher Dermarkarian (1) · Cristian Salgado (1) · Cuneyt M Alper, MD (1) · Cyril Clarke, BSc MB BS MFPM (1) · Dolly Parasrampuria, PhD (1)
PMID 10662747, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15710782, PMID 15725047, PMID 15738343, PMID 17515447, PMID 17515448, PMID 20203244, PMID 20837887, PMID 21377716, PMID 22289724, PMID 22311903, PMID 23690356, PMID 26133030, PMID 26143019, PMID 27271310, PMID 34233378, PMID 36480111, PMID 36996503, PMID 37402024, PMID 39727053, PMID 42843159, PMID 9727818
2014 (1), P50DC007667 (1)